D. Boral Capital Reaffirms Buy Rating for Invivyd (NASDAQ:IVVD)

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating reiterated by equities research analysts at D. Boral Capital in a report released on Friday,Benzinga reports. They currently have a $9.00 price objective on the stock.

A number of other equities analysts also recently issued reports on the company. HC Wainwright lowered their price target on Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. EF Hutton Acquisition Co. I raised shares of Invivyd to a “strong-buy” rating in a research note on Wednesday, October 30th. Finally, Morgan Stanley cut their price target on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a report on Wednesday, November 20th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Invivyd presently has an average rating of “Buy” and a consensus price target of $7.89.

Invivyd Stock Performance

Shares of NASDAQ IVVD opened at $0.46 on Friday. The company’s fifty day moving average price is $0.65 and its 200 day moving average price is $0.91. The company has a market capitalization of $55.20 million, a PE ratio of -0.24 and a beta of 0.64. Invivyd has a 1 year low of $0.40 and a 1 year high of $5.20.

Insider Buying and Selling

In other news, Director Terrance Mcguire sold 160,400 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $0.59, for a total value of $94,636.00. Following the completion of the sale, the director now directly owns 4,202,679 shares in the company, valued at $2,479,580.61. This represents a 3.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders sold 816,466 shares of company stock worth $423,214. 17.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Invivyd

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. State Street Corp grew its position in Invivyd by 3.7% in the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after acquiring an additional 35,904 shares during the period. Marshall Wace LLP grew its holdings in shares of Invivyd by 4.2% during the 2nd quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock worth $866,000 after purchasing an additional 31,992 shares during the period. Acadian Asset Management LLC increased its position in shares of Invivyd by 232.0% during the 2nd quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock worth $745,000 after purchasing an additional 474,301 shares during the last quarter. Duquesne Family Office LLC purchased a new stake in Invivyd in the 2nd quarter valued at about $629,000. Finally, Renaissance Technologies LLC acquired a new position in Invivyd in the second quarter valued at about $421,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.